JP2022524391A - 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 - Google Patents

合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 Download PDF

Info

Publication number
JP2022524391A
JP2022524391A JP2021553767A JP2021553767A JP2022524391A JP 2022524391 A JP2022524391 A JP 2022524391A JP 2021553767 A JP2021553767 A JP 2021553767A JP 2021553767 A JP2021553767 A JP 2021553767A JP 2022524391 A JP2022524391 A JP 2022524391A
Authority
JP
Japan
Prior art keywords
replicon rna
oncolytic virus
synthetic oncolytic
virus
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021553767A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020185293A5 (en17
Inventor
アーバイン，ダレル，ジェイ．
ウィトラップ，カール，デーン
ワイス，ロン
リー，インジョン
ムミン，ノア
ドン，イージョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2022524391A publication Critical patent/JP2022524391A/ja
Publication of JPWO2020185293A5 publication Critical patent/JPWO2020185293A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2021553767A 2019-03-08 2020-01-10 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 Pending JP2022524391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
US62/815,611 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Publications (2)

Publication Number Publication Date
JP2022524391A true JP2022524391A (ja) 2022-05-02
JPWO2020185293A5 JPWO2020185293A5 (en17) 2023-01-23

Family

ID=69526302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021553767A Pending JP2022524391A (ja) 2019-03-08 2020-01-10 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用

Country Status (13)

Country Link
US (2) US11717548B2 (en17)
EP (1) EP3934673A1 (en17)
JP (1) JP2022524391A (en17)
KR (1) KR20220006041A (en17)
CN (1) CN113966221A (en17)
AU (1) AU2020233788A1 (en17)
BR (1) BR112021017637A8 (en17)
CA (1) CA3132714A1 (en17)
CO (1) CO2021013417A2 (en17)
IL (1) IL285963A (en17)
MX (1) MX2021010808A (en17)
SG (1) SG11202109514VA (en17)
WO (1) WO2020185293A1 (en17)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180147166A1 (en) * 2015-05-21 2018-05-31 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP4180057A1 (en) * 2010-07-06 2023-05-17 GlaxoSmithKline Biologicals S.A. Virion-like delivery particles for self-replicating rna molecules
EP3188760B1 (en) * 2014-09-05 2023-12-06 Novartis AG Lipids and lipid compositions for the delivery of active agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180147166A1 (en) * 2015-05-21 2018-05-31 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELLULAR AND MOLECULAR BIOENGINEERING, vol. 11(5), JPN6023050883, 2018, pages 397 - 406, ISSN: 0005217068 *
NANO LETTERS, vol. 17(3）, JPN6023050884, 2017, pages 1326 - 1335, ISSN: 0005217067 *
VACCINES, vol. 4(4):39, JPN6023050885, 2016, pages 1 - 23, ISSN: 0005217066 *

Also Published As

Publication number Publication date
US20240024394A1 (en) 2024-01-25
CA3132714A1 (en) 2020-09-17
KR20220006041A (ko) 2022-01-14
WO2020185293A1 (en) 2020-09-17
US20200281994A1 (en) 2020-09-10
BR112021017637A2 (en17) 2021-11-09
CO2021013417A2 (es) 2022-01-17
AU2020233788A1 (en) 2021-10-07
EP3934673A1 (en) 2022-01-12
US11717548B2 (en) 2023-08-08
BR112021017637A8 (pt) 2022-08-16
MX2021010808A (es) 2021-12-15
IL285963A (en) 2021-10-31
SG11202109514VA (en) 2021-09-29
CN113966221A (zh) 2022-01-21

Similar Documents

Publication Publication Date Title
US11369634B2 (en) Exosome-based therapeutics against neurodegenerative disorders
US11826384B2 (en) Genetic engineering of macrophages for immunotherapy
Pardi et al. mRNA vaccines—a new era in vaccinology
US20240024394A1 (en) Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Machhi et al. A role for extracellular vesicles in SARS-CoV-2 therapeutics and prevention
US20200224174A1 (en) Methods for in vitro evolution of constructs derived from viruses
JP2023514594A (ja) コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法
Loomis et al. Strategies for modulating innate immune activation and protein production of in vitro transcribed mRNAs
US20210205475A1 (en) Mitochondrial optogenetics-based gene therapy for treating cancer
Huang et al. Advances in development of mRNA-based therapeutics
Fekrirad et al. Immunology meets bioengineering: Improving the effectiveness of glioblastoma immunotherapy
Nakamura et al. Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles
KR20210082186A (ko) 폐 염증 요법을 위한 나노담체
Zhao et al. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Pascolo Nonreplicating synthetic mRNA vaccines: A journey through the European (Journal of Immunology) history
US20240166707A1 (en) Expression constructs and uses thereof
JP6702938B2 (ja) アンタゴニストｉｃ ｃｔｌａ−４アプタマー及びその免疫活性増強への応用
Zeng et al. Micro Trojan horses: Engineering extracellular vesicles crossing biological barriers for drug delivery
JP2023536844A (ja) ワクチン接種を改善するための組成物および方法
RU2809724C2 (ru) Синтетический онколитический lnp-репликон рнк и применения для иммунотерапии злокачественных опухолей
WO2023212618A1 (en) Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
Nie et al. DNA nanodevice as a multi-module co-delivery platform for combination cancer immunotherapy
Brown Development of Genetic Medicines for the Treatment and Prevention of Infectious Disease, Cancer, and Aging
JP2024509084A (ja) 核酸ベクター及び使用方法
Jin et al. Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611